Q32 Bio Inc. reported its financial results for the second quarter ended June 30, 2025, announcing a net loss of $9.489 million. This represents an improvement from the $16.978 million net loss reported in the same period of 2024. The net loss per share was $0.78 for the quarter.
For the six months ended June 30, 2025, the net loss was $20.520 million, compared to $15.949 million in 2024. This change was influenced by a noncash gain of $15.890 million from the change in fair value of convertible notes in the prior year, which did not recur. Research and development expenses for the quarter decreased significantly to $5.161 million from $13.411 million in Q2 2024, primarily due to a $6.25 million reduction in bempikibart development costs and a $0.60 million decrease in ADX-097 direct R&D expenses following its discontinuation.
General and administrative expenses also decreased by $0.50 million to $4.010 million, mainly due to reduced personnel costs from the restructuring. As of June 30, 2025, Q32 Bio held $54.832 million in cash and cash equivalents, which management now expects will fund operations into 2027. This extends the previous cash runway projection into the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.